- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1559KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 445KB)
Olaparib – March 2021
Olaparib: Tablet 150 mg, Tablet 100 mg; Lynparza®
Last updated
16 July 2021